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Objectives: Data on consumption of penicillins in the community were collected from 30 EU/European
Economic Area (EEA) countries over two decades. This article reviews temporal trends, seasonal variation,
presence of change-points and changes in the composition of the main subgroups of penicillins.
Methods: For the period 1997–2017, data on consumption of penicillins, i.e. b-lactam antibacterials, penicil-
lins (ATC group J01C), in the community aggregated at the level of the active substance, were collected using
the WHO ATC/DDD methodology (ATC/DDD index 2019). Consumption was expressed in DDD per 1000 inhabi-
tants per day and in packages per 1000 inhabitants per day. Consumption of penicillins was analysed
based on ATC-4 subgroups, and presented as trends, seasonal variation, presence of change-points and
compositional changes.
Results: In 2017, consumption of penicillins in the community expressed in DDD per 1000 inhabitants
per day varied by a factor of 4.9 between countries with the highest (Spain) and the lowest (the
Netherlands) consumption. An increase in consumption of penicillins, which was not statistically
significant, was observed between 1997 and 2003 and up to 2010. A decrease, which was not statistically
significant, was observed from 2010 onwards. Proportional consumption of combinations of penicillins,
including b-lactamase inhibitors (J01CR) increased during 1997–2017, which coincided with a decrease in
the proportional consumption of extended-spectrum penicillins (J01CA) and narrow-spectrum penicillins
(J01CE).
Conclusions: Considerable variation in the patterns of consumption of penicillins was observed between EU/EEA
countries. The consumption of penicillins in the EU/EEA community did not change significantly over time, while
the proportional consumption of combinations of penicillins increased.
Introduction
This article presents data from the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net,1 formerly ESAC)
on consumption of penicillins for 30 EU/European Economic Area
(EEA) countries in 2017 (Table 1). It updates previous ESAC studies
published in 2006 and 2011, and in doing so it provides updated
comparable and reliable information on antibiotic consumption
that can aid in fighting the global problem of antimicrobial resist-
ance.2,3 In 2017, penicillins represented 42.3% of antibiotic con-
sumption in the community.4 The objective of this study was to
analyse temporal trends, seasonal variation and the presence of
change-points in consumption of penicillins in the community
(i.e. primary care sector) for the period 1997–2017, as well as to
analyse the composition of consumption of penicillins over time.
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.4 In summary, data on consumption of
penicillins, i.e. b-lactam antibacterials, penicillins (ATC group J01C, referred
to as penicillins in this manuscript) aggregated at the level of the active
substance, were collected using the WHO ATC/DDD methodology (ATC/DDD
index 2019)5 and expressed in DDD per 1000 inhabitants per day. In add-
ition, where data were available, consumption of penicillins was expressed
in packages per 1000 inhabitants per day. Penicillins (J01C) are classified in
five subgroups. Because b-lactamase inhibitors (J01CG) are given in
conjunction with extended-spectrum penicillins (J01CA), we focused on
only the four main subgroups: penicillins with extended-spectrum [J01CA;
extended-spectrum penicillins (ESP)], b-lactamase-sensitive penicillins
[J01CE; narrow-spectrum penicillins (NSP)]; b-lactamase-resistant penicil-
lins [J01CF; penicillinase-resistant penicillins (PRP)], and combinations of
penicillins including b-lactamase inhibitors [J01CR; combinations of penicil-
lins (COP)].
There are 46 unique ATC codes for penicillins in the ATC/DDD index
2019. Compared with previous descriptions of the consumption of penicil-
lins in the community, two additional substances, i.e. nafcillin (J01CF06)
and aspoxicillin (J01CA19), have been assigned an ATC code by the WHO
(Table 1).2
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal vari-
ation and presence of change-points in consumption of penicillins were
assessed using a non-linear change-point mixed model fitted to quarterly
data expressed in DDD per 1000 inhabitants per day from 1997 to 2017.6
The relative proportions of the main subgroups were assessed through a
compositional data analysis modelling yearly data expressed in DDD per
1000 inhabitants per day from 1997 to 2017.7
Results
An overview of consumption of penicillins (ATC J01C) in the
community, expressed in DDD and packages per 1000 inhabitants
per day for all participating countries between 1997 and 2017 is
available as Supplementary data at JAC Online (Tables S1 and S2,
respectively).
Consumption of penicillins in the community in 2017
In 2017, four substances accounted for 90% of the consumption
of penicillins in the community expressed in DDD per 1000 inhabi-
tants per day: amoxicillin/clavulanic acid (45.9% in 2017 compared
with 42.4% in 2009), amoxicillin (34.8% in 2017 compared with




































Combinations of penicillins, including b-lactamase inhibitors
J01CR01 Ampicillin and BLI
J01CR02 Amoxicillin and BLIb
J01CR03 Ticarcillin and BLI
J01CR04 Sultamicillin
J01CR05 Piperacillin and BLI












BLI, b-lactamase inhibitor; Bold type indicates that consumption was
part of the top 90% of the community consumption of penicillins (J01C)
in 28 EU/EEA countries in 2017; Italic type indicates that no consumption
of this penicillin was reported in 28 EU/EEA countries in 2017.
aNo consumption of this penicillin was reported in 30 EU/EEA countries in
2009.
bConsumption was part of the top 90% of community consumption of
penicillins (J01C) in 30 EU/EEA countries in 2009.
cThis penicillin was not included in the ATC/DDD index in 2009 and was
therefore not reported in 2009.
Table 1. Continued
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34.7% in 2009), phenoxymethylpenicillin (9% in 2017 compared
with 12.9% in 2009) and flucloxacillin (3.2% in 2017 compared
with 2.5% in 2009) (Table 1).
Figure 1 shows the consumption of penicillins in the community
subdivided in the four main subgroups expressed in DDD per 1000
inhabitants per day for 30 EU/EEA countries in 2017. Consumption
of penicillins in the community varied by a factor of 4.9 between
the countries with the highest (14.23 DDD per 1000 inhabitants per
day in Spain) and the lowest (2.92 DDD per 1000 inhabitants per
day in the Netherlands) consumption in 2017, which was higher
than in 2009 (factor of 3.6, from 10.91 DDD per 1000 inhabitants
per day in France to 3.03 DDD per 1000 inhabitants per day in
Estonia).
In 2017, NSP represented 10.1% (compared with 15.1% in
2009) of penicillin consumption in the community. Large variations
in NSP consumption were found, ranging from 3.8 DDD per 1000
inhabitants per day in Denmark to 0.0006 DDD per 1000 inhabi-
tants per day in Italy. Phenoxymethylpenicillin, commonly known
as penicillin V, was the most widely reported NSP in most countries.
It represented >50% of penicillin consumption in the community
in Sweden (53.8%) and Norway (53.5%), but represented <1% of
penicillin consumption in Belgium, Cyprus (total care data, i.e. com-
munity and hospital sector combined), Greece, Luxembourg, the
Netherlands and Spain, with no consumption reported in Italy,
Portugal and Slovenia. A wide variety of other NSPs was reported,
which varied depending on the countries. For example, benzathine
phenoxymethylpenicillin was mainly consumed in Austria, Croatia,
Germany and Slovenia, and benzylpenicillin in Greece and
Romania (total care data). Pheneticillin was exclusively consumed
in the Netherlands, and procaine benzylpenicillin was exclusively
consumed in Spain.
In 2017, ESP represented 38.6% (compared with 37.8% in
2009) of penicillin consumption in the community. ESP consump-
tion ranged from 8.2 DDD per 1000 inhabitants per day in France
to 0.37 DDD per 1000 inhabitants per day in Malta. Amoxicillin was
by far the most commonly reported ESP. It represented >50% of
penicillin consumption in the community in Lithuania (72.2%),
Germany (68.4%), Latvia (64.0%), France (62.0%), Bulgaria
(53.7%), Poland (52.4%) and the United Kingdom (51.2%). Malta
had the lowest proportional consumption (5.0%). Pivmecillinam
was commonly reported in Denmark (26.2%), Norway (23.2%),
Finland (14.0%) and Iceland (13.0%). Mecillinam was only
reported in Greece and Norway; pivampicillin was only reported in
Denmark; and bacampicillin and piperacillin were only reported in
Italy.
In 2017, COP represented 46.3% (compared with 42.8% in
2009) of penicillin consumption in the community. COP consump-
tion ranged from 7.85 DDD per 1000 inhabitants per day in Spain
to 0.01 DDD per 1000 inhabitants per day in Norway. Amoxicillin/
clavulanic acid was the most commonly reported COP. It repre-
sented >50% of penicillin consumption in the community in Malta
(91.7%), Hungary (80.1%), Cyprus (76.6%; total care data), Italy
(76.5%), Portugal (70.2%), Austria (68.5%), Croatia (68.2%),
Romania (56.9%; total care data), Spain (55.2%), Greece (55.2%)
and Luxembourg (53.8%), but <5% in Sweden (3.4%). Sultamicillin
consumption remained <1% of penicillin consumption in the com-
munity for all countries but Estonia (2.4%), Germany (2.2%) and
Lithuania (1.5%).
In 2017, PRP represented 5.0% (compared with 4.3% in
2009) of penicillin consumption in the community. PRP con-
sumption ranged from 1.56 DDD per 1000 inhabitants per day in
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Figure 1. Consumption of penicillins (ATC J01C) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/EEA
countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and hos-
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Estonia, with no consumption reported in Bulgaria and Hungary.
Flucloxacillin was the most commonly reported PRP. It repre-
sented >20% of penicillin consumption in the community in
Sweden (25.2%) and the United Kingdom (23.7%) while it was
not reported in Cyprus (total care data), France, Greece,
Lithuania, Poland and Spain. With the exception of Lithuania,
countries without flucloxacillin consumption reported con-
sumption of cloxacillin as the sole PRP.
Figure 2 shows consumption of penicillins in the community
expressed in packages per 1000 inhabitants per day for 20 EU/EEA
countries in 2017. Based on this indicator, France showed the high-
est consumption (2.7 packages per 1000 inhabitants per day)
while Sweden showed the lowest consumption (0.5 packages per
1000 inhabitants per day). Denmark shifted from rank 6 for its con-
sumption of penicillins in DDD per 1000 inhabitants per day
(among the highest prescribing countries) to rank 12 in packages
per 1000 inhabitants per day (among the lowest prescribing
countries), Spain moved from the 1st to the 4th rank and
Sweden from the 15th to the 20th rank, while Italy moved
from the 8th to the 3rd rank (Table 2). The lowest mean number of
DDD per package was observed for France (4.9 DDD per package)
and the highest for Spain and Sweden (10.7 DDD per package).
In the EU/EEA, the number of DDD per package increased signifi-
cantly over time [!0.099 (SD 0.0274) DDD per year] during 1997–
2017.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including two change-points:
one in the first quarter of 2003 and another in the second quarter
of 2010. The final model fits the observed data well (Figure S1).
The longitudinal data analysis estimated an average consumption
of penicillins in the EU/EEA of 6.717 (SE 0.501) DDD per 1000 inhab-
itants per day in the first quarter of 1997, which did not change sig-
nificantly over time: !0.004 (SE 0.011) DDD per 1000 inhabitants
per day per quarter until the first quarter of 2003; !0.022 (SE
0.019) DDD per 1000 inhabitants per day per quarter between the
second quarter of 2003 and the second quarter of 2010; and
!0.008 (SE 0.030) DDD per 1000 inhabitants per day per quarter
afterwards. Furthermore, the longitudinal data analysis showed
significant seasonal variation with an amplitude of 1.413 (SE
0.164) DDD per 1000 inhabitants per day, which did not change
significantly over time: #0.002 (SE 0.001) DDD per 1000 inhabi-
tants per day per quarter (Figure 3).
Based on the final fitted model, consumption of penicillins in
the community in 1997 was significantly above average in Iceland
and Slovakia, and significantly below average in Estonia, Finland,
Germany, the Netherlands and the United Kingdom (observed
profiles shown in Figures S2 and S3). The seasonal variation was
significantly larger than average in Belgium, Italy, Lithuania,
Luxembourg and Slovakia, and significantly smaller than average
in Austria, Estonia, Finland, Germany, Greece, the Netherlands,
Sweden and the United Kingdom. The increase in consumption of
penicillins in the community between 1997 and the first quarter of
2003 was significantly larger than average in Croatia, Denmark
and Poland. The increase in consumption of penicillins between
the second quarter of 2003 and the second quarter of 2010
was significantly larger than average in Belgium, Italy and
Luxembourg. The increase in consumption of penicillins between
the third quarter of 2010 and the last quarter of 2017 was signifi-













































































































Narrow-spectrum penicillins (J01CE) Extended-spectrum penicillins (J01CA)
Penicillinase-resistant penicillins (J01CF)Combinations of penicillins, incl. b-lacatamase inhibitors (J01CR)
Figure 2. Consumption of penicillins (ATC J01C) in the community, expressed in packages per 1000 inhabitants per day, 20 EU/EEA countries, 2017.
For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and hospital sector com-
bined, are used.
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Compositional data analysis, 1997–2017
The proportional consumption of ESP and COP significantly
increased over time relative to that of NSP and PRP. In addition, the
proportional consumption of COP significantly increased over time
relative to that of ESP (Table 3).
Trends of proportional consumption of penicillins in the com-
munity for individual countries are shown in Figure S4. When com-
paring the composition of the consumption of penicillins (J01C) in
2017 with that in 2009, the proportion of NSP decreased for most
of the participating countries. The largest decreases were observed
for Denmark (#13.74%), Lithuania (#10.77%) and Hungary
(#10.70%). However, increases were also observed, with the larg-
est increases reported for Poland (!2.58%), Malta (!1.45%) and
Romania (!1.42%; total care data; coverage in 2009 limited to
30%–40%). For the proportions of ESP, COP and PRP, both increases
and decreases were observed between 2009 and 2017. For ESP,
the largest increases were reported for Belgium (!10.12%), France
(!7.80%) and Spain (!7.06%; private prescriptions included from
2016 onwards), while the largest decreases were reported for
Estonia (#18.63%), Cyprus (#14.29%; total care data) and Italy
(#12.64%). For COP, the largest increases were reported for
Estonia (!21.84%), Croatia (!18.72%) and Hungary (!18.16%),
while the largest decreases were reported for Belgium (#9.37%),
Luxembourg (#8.24%) and Ireland (#7.09%). For PRP, the largest
increases were reported for the United Kingdom (!4.59%),
the Netherlands (!4.15%) and Denmark (!4.10%), while the larg-
est decreases were reported for France (#2.75%) and Iceland
(#2.23%).
Discussion
Penicillins (J01C) were the most frequently consumed antibiotics in
the community in the EU/EEA in 2017.4 Consumption of penicillins
in European countries that are not part of the ESAC-Net but cov-
ered by the WHO Europe Antimicrobial Medicines Consumption
Network also was substantial, ranging from 28% in Kazakhstan to
52.5% in Uzbekistan.8
In the EU/EEA, consumption of penicillins in the community
remained high and stable between 1997 and 2017. Inter-country
variability of consumption of penicillins in the community
expressed in DDD per 1000 inhabitants per day was substantial,
and increased when compared with data from 2009. Seasonal
variation was high and remained stable over time.
Among the 46 penicillins with an ATC code, more substances
were no longer prescribed in 2017 (21 out of 46) than in
2009 (12 out of 44). Overall, COP was the most frequently con-
sumed subgroup of penicillins. Proportional consumption of
COP increased in most countries at the expense of consumption
of NSP or ESP. Given that total consumption of penicillins did not
change significantly over time between 1997 and 2017, this
implies that consumption of antibiotics from one subgroup was
merely replaced by consumption of antibiotics from another
subgroup, rather than being reduced overall. In Belgium, a 10%
decrease in consumption of COP was accompanied by a 10%
increase in consumption of ESP, most likely as the result of
successful multi-faceted campaigning in the country.9 Country-
specific consumption of COP showed great variability, ranging
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DDD per 1000 inhabitants per day in Norway. The most
frequently reported substance was amoxicillin/clavulanic acid,
which represented >50% of penicillin consumption in the com-
munity in 11 countries. This finding, once again, raises concern
about the appropriate prescribing of amoxicillin/clavulanic
acid for respiratory tract infections (RTIs).10
Given that the mean number of DDD per package varied consid-
erably and increased over time,11 and that antimicrobial resistance
best correlates with consumption expressed in packages,12 we
recommend evaluating antibiotic consumption expressed both
in DDD per 1000 inhabitants per day and in packages per 1000
inhabitants per day.
With the exception of four penicillins that represented <1% of
penicillin consumption in the community in EU/EEA countries, the
penicillins used were listed in the 2019 WHO Access, Watch or
Reserve (AWaRe) classification list.13 Most penicillins are listed
as antibiotics belonging to the Access group. The antibiotics
listed in the Watch group, which include pheneticillin (J01CE05),
piperacillin (J01CA12), piperacillin and b-lactamase inhibitor
(J01CR05) and temocillin (J01CA17), are mainly used in the hos-
pital sector (consumption of these antibiotics in the community
was <1% in the EU/EEA in 2017). Care should be taken by
countries to optimize the availability of penicillins that belong
to the Access group.
The continued seasonal variation in consumption of penicil-
lins in the community found in this study confirms that penicil-
lins are still prescribed for seasonal RTIs, which represent nearly
60% of antibiotic prescriptions in the community, even though
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of penicillins (ATC J01C) in the community based on quarterly
data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase (if positive)/decrease (if negative)
in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted difference in slope after versus
before the second change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, predicted amplitude of the upward
winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the amplitude of the upward winter
and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and downward summer peak from one year to an-
other. *Statistically significant at significance level 0.05.
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RTIs are mostly viral in origin.14–16 Based on this finding, acute
RTIs remain an ideal opportunity for antimicrobial stewardship
activities in the community in EU/EEA countries.
For a detailed discussion on the limitations of the collected
data, we refer to the article on antibacterials for systemic use,
included in this series.17 For a discussion on the limitations of the
statistical approach used in this study and potential explanations
for the common change-points detected through these analyses,
we refer to the tutorial included in this series.6
In conclusion, neither the consumption nor the seasonal vari-
ation in consumption of penicillins in the community changed over
time. However, the proportional consumption of COP increased
significantly over time during 1997–2017.
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